Alembic Pharmaceuticals Limited (IN:APLLTD)
:APLLTD
Want to see IN:APLLTD full AI Analyst Report?
Total Valuation
Alembic Pharmaceuticals Limited has a market cap or net worth of ₹147.95B. The enterprise value is ₹160.16B.
Market Cap₹147.95B
Enterprise Value₹160.16B
Share Statistics
Alembic Pharmaceuticals Limited has 196,563,130 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding196,563,130
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Alembic Pharmaceuticals Limited’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 10.40%.
Return on Equity (ROE)0.12
Return on Assets (ROA)0.08
Return on Invested Capital (ROIC)10.40%
Return on Capital Employed (ROCE)0.13
Revenue Per Employee4.94M
Profits Per Employee454.15K
Employee Count14,858
Asset Turnover0.84
Inventory Turnover1.61
Valuation Ratios
The current PE Ratio of Alembic Pharmaceuticals Limited is 19.3. Alembic Pharmaceuticals Limited’s PEG ratio is 1.23.
PE Ratio19.3
PS Ratio1.77
PB Ratio2.30
Price to Fair Value2.30
Price to FCF50.01
Price to Operating Cash Flow36.71
PEG Ratio1.23
Income Statement
In the last 12 months, Alembic Pharmaceuticals Limited had revenue of 73.45B and earned 6.75B in profits. Earnings per share was 34.33.
Revenue73.45B
Gross Profit33.10B
Operating Income8.00B
Pretax Income6.94B
Net Income6.75B
EBITDA11.18B
Earnings Per Share (EPS)34.33
Cash Flow
In the last 12 months, operating cash flow was 4.03B and capital expenditures -2.34B, giving a free cash flow of 1.69B billion.
Operating Cash Flow4.03B
Free Cash Flow1.69B
Free Cash Flow per Share8.59
Dividends & Yields
Alembic Pharmaceuticals Limited pays an annual dividend of ₹11, resulting in a dividend yield of 1.28%
Dividend Per Share₹11
Dividend Yield1.28%
Payout Ratio34.06%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.01
52-Week Price Change-20.88%
50-Day Moving Average726.41
200-Day Moving Average844.14
Relative Strength Index (RSI)49.28
Average Volume (3m)9.71K
Important Dates
Alembic Pharmaceuticals Limited upcoming earnings date is Jul 31, 2026, TBA (Confirmed).
Last Earnings DateMay 15, 2026
Next Earnings DateJul 31, 2026
Ex-Dividend Date―
Financial Position
Alembic Pharmaceuticals Limited as a current ratio of 1.76, with Debt / Equity ratio of 25.20%
Current Ratio1.76
Quick Ratio0.79
Debt to Market Cap0.11
Net Debt to EBITDA1.10
Interest Coverage Ratio8.54
Taxes
In the past 12 months, Alembic Pharmaceuticals Limited has paid 231.20M in taxes.
Income Tax231.20M
Effective Tax Rate0.03
Enterprise Valuation
Alembic Pharmaceuticals Limited EV to EBITDA ratio is 12.75, with an EV/FCF ratio of 54.72.
EV to Sales1.94
EV to EBITDA12.75
EV to Free Cash Flow54.72
EV to Operating Cash Flow20.51
Balance Sheet
Alembic Pharmaceuticals Limited has ₹1.55B in cash and marketable securities with ₹14.89B in debt, giving a net cash position of -₹13.34B billion.
Cash & Marketable Securities₹1.55B
Total Debt₹14.89B
Net Cash-₹13.34B
Net Cash Per Share-₹67.84
Tangible Book Value Per Share₹288.42
Margins
Gross margin is 51.83%, with operating margin of 10.89%, and net profit margin of 9.19%.
Gross Margin51.83%
Operating Margin10.89%
Pretax Margin9.45%
Net Profit Margin9.19%
EBITDA Margin15.23%
EBIT Margin10.89%
Analyst Forecast
The average price target for Alembic Pharmaceuticals Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast10.08%
EPS Growth Forecast15.65%